Apremilast tablets show promise in genital psoriasis

Genital psoriasis , especially when pustular symptoms are present, represents a rare and diagnostically challenging subtype of the disease. A retrospective case series was published evaluating the efficacy of the oral phosphodiesterase 4 (PDE4) inhibitor apremilast (Apremilast) in the treatment of this underappreciated disease in men with refractory disease. These findings provide new insights into a potential treatment option for patients who have exhausted topical and traditional systemic therapies.

1. Background and clinical challenges

Patients with genital psoriasis may experience significant physical discomfort, sexual dysfunction, and psychosocial distress. Systemic treatment is often required due to anatomical sensitivity and limited efficacy of traditional topical agents such as corticosteroids and calcineurin inhibitors. However, commonly used drugs such as methotrexate, acitretin, and cyclosporine carry risks of hepatotoxicity, mucocutaneous adverse reactions, and patient intolerance, limiting their long-term utility.

Biologic therapies likeixekizumab have shown promise but are often inaccessible to patients with limited disease involvement, such as those with genital psoriasis. 3 This treatment gap highlights the need for alternatives such as apremilast, which has a superior safety profile and the convenience of oral administration.

2. Research design and methods

The study included6 men aged 21 to 47 years with pustular features histologically confirmed to be located on the glans penis or glans and foreskin. All patients had a clinical history of annular balanitis and had failed multiple previous treatments, including potent topical steroids, tacrolimus, acitretin, methotrexate, and cyclosporine. Of note, diagnostic workup for sexually transmitted infections and systemic features of reactive arthritis were negative in all cases.

The patient was started on apremilast according to a standard 6-day titration schedule, reaching a maintenance dose of 30 mg twice daily. One patient required dose adjustment to once daily due to migraine. Follow-up is from 1 to 3 months.

3. Results

AllSix patients achieved complete clinical remission within 1 to 3 months of treatment initiation. Adverse effects were minor and transient, with diarrhea being the most commonly reported but self-limiting within 2 weeks. During the study period, no patients exhibited extragenital psoriasis or psoriatic arthritis, and no patients required adjuvant therapy.

Histopathological findings supported the diagnosis of pustular psoriasis, but variability in its presentation was noted, particularly in the genital area. Although intraepidermal neutrophil microabscesses and parakeratosis are present, fully formed pustules are usually absent, highlighting the importance of correlating histology with clinical features such as annular (ring-shaped) lesions.

4. Clinical significance

The rapid and complete responses seen in all cases support apremilast as a potentially effective and well-tolerated treatment for refractory genital psoriasis with pustular features. Its mechanism—targeting pro-inflammatory cytokines through PDE4 inhibition—makes it particularly suitable for local diseases where inflammation is dominant.

Given the rarity of the condition and the small cohort studied, the researchers said the findings should be interpreted with caution. However, they are consistent with previous reports on the efficacy of apremilast in challenging psoriasis manifestations such as palmoplantar pustulosis and genital involvement. Importantly, ease of administration and low incidence of serious adverse effects facilitate use in sensitive anatomical locations.

By providing a nonbiologic oral treatment option with a favorable safety profile, apremilast may bridge an important treatment gap for patients who face limited options due to anatomical site or contraindications to treatment.

Reference materials:https://go.drugbank.com/drugs/DB05676